Hearts and Minds donates almost $10m to charity

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 medical research this week, in addition to the $4.1 million it already donated in March. [Financial Standard]

Ally Selby

Hearts and Minds donates almost $10m to charity

September 1, 2020
Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 medical research this week, in addition to the $4.1 million it already donated in March. [Financial Standard]
Read Transcript

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 charities this week, in addition to the $4.1 million it already donated in March.

HM1 and its participating fund managers forego any investment or management fees and instead donate 1.5% of its net tangible assets per annum to various medical research institutes and charities.

HM1's core fund managers, who provide the listed investment company with their three highest conviction ideas, include Will Vicars and Michael Messara from Caledonia Investments; Peter Cooper from Cooper Investors; Hamish Douglass from Magellan; Philip King from Regal Funds Management; David Paradice from Paradice Investments; and Hamish Corlett and Tom Cowan from TDM Growth Partners.

The $5.1 million will be split across 10 medical research houses and charities, including The Victor Chang Cardiac Research Institute; The Florey Institute of Neuroscience and Mental Health; Swinburne's Centre for Psychopharmacology; RPA Green Light Institute; Black Dog Institute; Orygen; Charlie Teo Foundation; MS Research Australia; Kids Critical Care at Westmead Hospital; and the Brain and Mind Centre within the University of Sydney.

"These donated monies will be used by the medical research organisations to fund important research into the prevention and treatment of chronic diseases and mental health disorders," HM1 said in its annual report.

"The current pandemic highlights the critical importance of medical research to global health outcomes and economic prosperity."

HM1 recently reported a pre-tax investment return of 26.1% for the year ending  June 30, significantly outperforming its global benchmark (MSCI World Net TR), which increased 4.8% over the financial year.

Since its inception in November 2018, HM1 has generated a pre-tax return of 51.3%, compared to the benchmark's 18.2% over the same nearly two year period.

It outperformed the same index by 19.7% over the past six months, returning 15.9% compared to the benchmark's -3.8%.

HM1 chief executive Paul Rayson believes this is in large thanks to the investment company's holdings in Tesla, which they have held since November last year.

"Tesla has been a standout, but we also invest in Appen which is up over 100%, we participated in Spotify, which is up over 75%, while Zillow Group, Microsoft, and our holdings in next tier tech companies have also performed well," he told Financial Standard.

The listed investment company's largest holding (as of June 30) is Mineral Resources (7.54%), followed by Zillow Group (6.96%), Alibaba (6.7%), and Spotify (5.76%).

More than 5% of the portfolio's holdings are invested in Tesla.

While the portfolio is concentrated in a relatively small number of securities (only 28 as of June 30), it is overweight to communications, technology and consumer discretionaries compared to its benchmark.

"These sectors have performed well over the past year or two, but no one can predict the future," Rayson said.

"The way our model works is that we invest in the highest conviction ideas from our fund managers."

It is underweight to financials, utilities, healthcare and materials compared to the MSCI World Index.

Only six of the companies that HM1 invests in have a market cap over ~$68 billion (US$50 billion), while its smallest holding has a market cap of  $650 million.

 

This article was originally featured on Financial Standard here.

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 charities this week, in addition to the $4.1 million it already donated in March.

HM1 and its participating fund managers forego any investment or management fees and instead donate 1.5% of its net tangible assets per annum to various medical research institutes and charities.

HM1's core fund managers, who provide the listed investment company with their three highest conviction ideas, include Will Vicars and Michael Messara from Caledonia Investments; Peter Cooper from Cooper Investors; Hamish Douglass from Magellan; Philip King from Regal Funds Management; David Paradice from Paradice Investments; and Hamish Corlett and Tom Cowan from TDM Growth Partners.

The $5.1 million will be split across 10 medical research houses and charities, including The Victor Chang Cardiac Research Institute; The Florey Institute of Neuroscience and Mental Health; Swinburne's Centre for Psychopharmacology; RPA Green Light Institute; Black Dog Institute; Orygen; Charlie Teo Foundation; MS Research Australia; Kids Critical Care at Westmead Hospital; and the Brain and Mind Centre within the University of Sydney.

"These donated monies will be used by the medical research organisations to fund important research into the prevention and treatment of chronic diseases and mental health disorders," HM1 said in its annual report.

"The current pandemic highlights the critical importance of medical research to global health outcomes and economic prosperity."

HM1 recently reported a pre-tax investment return of 26.1% for the year ending  June 30, significantly outperforming its global benchmark (MSCI World Net TR), which increased 4.8% over the financial year.

Since its inception in November 2018, HM1 has generated a pre-tax return of 51.3%, compared to the benchmark's 18.2% over the same nearly two year period.

It outperformed the same index by 19.7% over the past six months, returning 15.9% compared to the benchmark's -3.8%.

HM1 chief executive Paul Rayson believes this is in large thanks to the investment company's holdings in Tesla, which they have held since November last year.

"Tesla has been a standout, but we also invest in Appen which is up over 100%, we participated in Spotify, which is up over 75%, while Zillow Group, Microsoft, and our holdings in next tier tech companies have also performed well," he told Financial Standard.

The listed investment company's largest holding (as of June 30) is Mineral Resources (7.54%), followed by Zillow Group (6.96%), Alibaba (6.7%), and Spotify (5.76%).

More than 5% of the portfolio's holdings are invested in Tesla.

While the portfolio is concentrated in a relatively small number of securities (only 28 as of June 30), it is overweight to communications, technology and consumer discretionaries compared to its benchmark.

"These sectors have performed well over the past year or two, but no one can predict the future," Rayson said.

"The way our model works is that we invest in the highest conviction ideas from our fund managers."

It is underweight to financials, utilities, healthcare and materials compared to the MSCI World Index.

Only six of the companies that HM1 invests in have a market cap over ~$68 billion (US$50 billion), while its smallest holding has a market cap of  $650 million.

 

This article was originally featured on Financial Standard here.

Disclaimer: This material has been prepared by Financial Standard, published on Sep 01, 2020. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
August 31, 2020

Dysfunctional' mental health system needs boost in wake of pandemic: experts

Experts are warning the current mental health system is ill-equipped to respond to a forecast 30 per cent spike in mental illness in the wake of the coronavirus pandemic.

Read More
August 10, 2020

Beneficiary Profile: RPA Green Light

Emergency departments are the frontline of health care, with one in seven Australians seeking help from a hospital emergency department every year. Our medical staff depend on research findings to help inform their responses to urgent patient needs.

Read More
June 25, 2020

Understanding biomarkers of cognition in the elderly

Swinburne researchers have been investigating the biomarkers for cognitive ageing in healthy elderly Australians to examine whether age associated cognitive decline can be reduced.

Read More
June 18, 2020

Settling the Mind: Mental Health and Coronavirus Webinar Series

The Black Dog Institute has put together a webinar series called "Settling the Mind", which shares evidence-based insights and resources to help you navigate the affects of Covid.

Read More
June 16, 2020

Charlie Teo Foundation: How hope keeps them going

The Charlie Teo Foundation takes a moment to celebrate 2 years of the Foundation (CTF) and the exciting projects they are funding to help in their fight against brain cancer.

Read More
June 9, 2020

Beneficiary Profile: Orygen

1 in 5 young people will have experienced a depressive episode by the time they are 18. With thanks to Cooper Investors and Hearts & Minds, we have been able to put youth mental health on the global agenda and progress our work in developing a global mental health framework.

Read More
May 3, 2020

New treatment giving severe COVID-19 patients a fighting chance

The Victor Chang Cardiac Research Institute featured on 7News discussing their latest Covid-19 collaborative project.

Read More
April 5, 2020

Victor Chang's Executive Director discusses the impact of Covid-19

Victor Chang Cardiac Research Institute's Executive Director Professor Jason Kovacic discusses Covid-19, its impact on the heart and their related research.

Read More
April 2, 2020

Coronavirus: Anxiety, Stress & Wellbeing

Black Dog Institute, one of our beneficiaries, has put together helpful, evidenced-based resources to help you, your workplaces, schools and parents during this time.

Read More
November 22, 2019

Impact Video Series: Brain and Mind Centre

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Centre for Human Psychopharmacology

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Charlie Teo Foundation

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: MS Research Australia

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Orygen

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Our Impact

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More